BB Biotech AG
ISIN: CH0038389992 | Ticker: BION | LEI: 391200MBZQNPFHIVKO34
Country: Switzerland
Since our foundation in 1993, we have offered investors direct access to a select portfolio of promising, fast growing and profitable biotech companies listed on stock markets around the world. Thanks to our strong track record over the years and our systematic strategy and clear focus, we have become one of the world’s largest biotech investors.
Biotechnology is one of the most attractive of any sector today with estimated annual growth in the double-digits. Mega trends such as increasing life expectancy and a westernized diet and lifestyle are powerful growth drivers. These mega trends have led to a tremendous increase in healthcare costs, which, in turn, only amplifies the need for more efficient and effective drugs.
1993
Served areaWorldwide
HeadquartersSchwertstrasse 6, 8200 Schaffhausen – Switzerland
| Line item in (chf) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Cash and cash equivalents | 30,707,000.00 | 6,816,000.00 | 2,835,000.00 | 1,948,000.00 |
| Other Current Liabilities | N/A | 5,709,000.00 | 5,431,000.00 | 4,143,000.00 |
| Line item in (chf) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue From Dividends | 243,000.00 | 0.00 | N/A |
| Profit (loss) | 691,174,000.00 | -404,808,000.00 | -357,812,000.00 |
| Line item in (chf) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | 691,174,000.00 | -404,808,000.00 | -357,812,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | -23,891,000.00 | -3,981,000.00 | -887,000.00 |
| Cash and cash equivalents | 30,707,000.00 | 6,816,000.00 | 2,835,000.00 | 1,948,000.00 |
Please note that some sums might not add up.
CH0038389992
LEI391200MBZQNPFHIVKO34
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.